logo
Share SHARE
FONT-SIZE Plus   Neg

Fitch Downgrades JPMorgan

Fitch Ratings said Friday that it has downgraded JPMorgan Chase & Co.'s (JPM) Long-term Issuer Default Rating to 'A+' from 'AA-' and its Short-term IDR to 'F1' from 'F1+'.

Fitch also has placed all parent and subsidiary long-term ratings on Rating Watch Negative.

The rating actions follow JPMorgan's disclosure Thursday of a $2 billion trading loss on its synthetic credit positions in its Chief Investment Office. The positions were intended to hedge the company's overall credit exposure, particularly during periods of credit stress.

While Fitch views the size of loss as manageable, it said the magnitude of the loss and ongoing nature of these positions implies a lack of liquidity.
"It also raises questions regarding JPM's risk appetite, risk management framework, practices and oversight; all key credit factors", the rating agency noted.

Fitch believes the potential reputational risk and risk governance issues raised at JPMorgan are no longer consistent with an 'AA-' rating.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of International Consolidated Airlines Group S.A. were gaining around 3 percent in London trading after the airline reported Friday higher profit in its second quarter, benefited by higher passenger revenues, despite weak cargo revenues. The company now expects low double digit percentage growth in pre-exceptional operating profit in 2016. Swiss banking giant UBS Group AG reported Friday a 14 percent decline in second quarter profit with weakness in net interest income. Looking ahead, the company said the difficult conditions continue to persist, yet the firm is well positioned to benefit from even a moderate improvement in conditions. UBS shares were gaining around 3 percent in the morning trading in Zurich. We are well into the third quarter and past the middle of the year and it is time to take stock of regulatory decisions awaiting some biotech stocks in August. Despite the uncertain macroeconomic environment, the markets have run up, with the S&P 500 Index making new highs session after session. Valuation concerns may keep traders at bay. However, the biotech space is a different cup of tea.
comments powered by Disqus
Follow RTT